CORE C ABSTRACT The Molecular Biology/Gene Expression Core Facility will provide critical services to support the scientific goals of this Program Project: 1) Molecular Reagent Bank- contains specific plasmids, expression constructs, reporter constructs, antibodies, RNA samples, and retroviral/adenoviral/lentiviral vectors of relevance to the study of esophageal carcinogenesis. As a result, these reagents have been organized and centralized. In addition, we will continue to store newly available reagents;2) Image Analysis and Gene Expression Quantification-multiple instruments are available, such as (but not limited to) Phosphorimaging, Gel and Chemidoc, Agilent Bioanalyzer and Odyssey Infrared Protein Imaging System, real-time quantitative PCR, and Luminometers for gene transcription analysis, a nanodrop, and flow cytometer;3) Genomic Services (subsidized) with gene microarrays (Affymetrix platform) through the Penn microarray facility, ultra-high throughput DNA sequencing for RNA- and CHIP-seq, and bioinformatics support;and 4) Esophageal Cell Line Bank (murine and human) with primary, immortalized, transformed and newly genetically engineered esophageal cell lines for use by the Projects. The Molecular Biology/Gene Expression Core provides quality assurance, quality control, cost-effectiveness, timeliness and efficiency in its services. This Core works closely with all the other Cores, especially the Molecular Pathology and Imaging Core (MPIC) to avoid duplication and furnish coordinated approaches for the Projects. The Projects benefit tremendously from this Core in advancing their interrelated hypotheses and Specific Aims. In addition, this Core is dynamic in responding to evolving P01 needs, anticipating future P01 directions, and integrating emerging technologies.

Public Health Relevance

The Molecular Biology/Gene Expression Core (MBC) provides a number of high technology services essential for the experiments focused on esophageal cancer that have been proposed by all three of the P01 investigators. These include access to expensive core equipment required for the analysis of protein, RNA, and DNA obtained from esophageal tissues and cell lines, ultra-high throughput DNA sequencing and bioinformatic analyses, as well as a repository of molecular reagents and esophageal cell lines. Interaction between the MBC and the other cores on this P01 provides the investigators with a dynamic and responsive environment the facilitates research into the biology of esophageal cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA098101-11
Application #
8741114
Study Section
Special Emphasis Panel (ZCA1-RPRB-O (M1))
Project Start
2002-12-01
Project End
2019-06-30
Budget Start
2014-08-01
Budget End
2015-06-30
Support Year
11
Fiscal Year
2014
Total Cost
$176,310
Indirect Cost
$49,848
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Barnoud, Thibaut; Budina-Kolomets, Anna; Basu, Subhasree et al. (2018) Tailoring Chemotherapy for the African-Centric S47 Variant of TP53. Cancer Res 78:5694-5705
Adeegbe, Dennis O; Liu, Shengwu; Hattersley, Maureen M et al. (2018) BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer. Cancer Immunol Res 6:1234-1245
Stachler, Matthew D; Camarda, Nicholas D; Deitrick, Christopher et al. (2018) Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma. Gastroenterology 155:156-167
Bockorny, Bruno; Rusan, Maria; Chen, Wankun et al. (2018) RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade. Mol Cancer Ther 17:1526-1539
Wong, Gabrielle S; Zhou, Jin; Liu, Jie Bin et al. (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med 24:968-977
Karakasheva, Tatiana A; Dominguez, George A; Hashimoto, Ayumi et al. (2018) CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients. JCI Insight 3:
Liu, Yang; Sethi, Nilay S; Hinoue, Toshinori et al. (2018) Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell 33:721-735.e8
Facompre, Nicole D; Harmeyer, Kayla M; Sahu, Varun et al. (2018) Targeting JARID1B's demethylase activity blocks a subset of its functions in oral cancer. Oncotarget 9:8985-8998
Deng, Jiehui; Wang, Eric S; Jenkins, Russell W et al. (2018) CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov 8:216-233
Karakasheva, Tatiana A; Lin, Eric W; Tang, Qiaosi et al. (2018) IL-6 Mediates Cross-Talk between Tumor Cells and Activated Fibroblasts in the Tumor Microenvironment. Cancer Res 78:4957-4970

Showing the most recent 10 out of 173 publications